RAPP – rapport therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $35.00 price target on the stock.
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Rapport Therapeutics Announces Pricing of Initial Public Offering
Form 4 Rapport Therapeutics, For: Jun 10 Filed by: ARCH Venture Partners XII, LLC
Form 4 Rapport Therapeutics, For: Jun 06 Filed by: Galer Bradley S.
Form 4 Rapport Therapeutics, For: Jun 06 Filed by: Bredt David
Form 4 Rapport Therapeutics, For: Jun 06 Filed by: Gault Cheryl
Form 4 Rapport Therapeutics, For: Jun 10 Filed by: TRV GP VI, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.